Connell and O'Reilly Families - Cell Manipulation Core Facility

Connell and O'Reilly Families
CELL MANIPULATION CORE FACILITY

  • HOME
  • SERVICES
  • HIGHLIGHTED PROJECTS
  • CONTACTS AND LOCATION
  • PUBLICATIONS
  • PRESENTATIONS
  • CAREERS with CMCF
  • CONNELL AND O'REILLY FAMILIES

Publications

A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. ​
PubMed

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Pubmed

An immunogenic personal neoantigen vaccine for patients with melanoma.. Pubmed

Biomanufacturing for clinically advanced cell therapies. Pubmed

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Pubmed

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.  Pubmed

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.  Pubmed

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Pubmed

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Pubmed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Pubmed

Global perspective on the development of genetically modified immune cells for cancer therapy. Pubmed

Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. Pubmed

Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. Pubmed

Comparative analysis of cell therapy infusion workflows at clinical sites. Pubmed
       Home | Services | Contacts and Location | Set-up New Protocol - IND | Publications | Presentations | Connell and O'Reilly Families |
© 2018 Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute